USPTO Proposes Major Restrictions on Inter Partes Review Patent Challenges

The United States Patent and Trademark Office (USPTO (搜索)搜索该词条) published proposed rule changes on October 17, 2025, that would fundamentally reshape the landscape of patent validity challenges by severely restricting access to Inter Partes Review (IPR) proceedings. The Notice of Proposed Rulemaking establishes a November 17, 2025 deadline for public comments on these potentially transformative changes to post-grant patent review.

Mandatory Stipulations Create All-or-Nothing Stakes

Under the proposed amendments to § 42.108(d), petitioners would be required to stipulate that they will not pursue any invalidity challenges under 35 U.S.C. §§ 102 or 103 in other venues if the Patent Trial and Appeal Board (搜索)搜索该词条 (PTAB) institutes IPR. This requirement goes significantly beyond current estoppel provisions under 35 U.S.C. § 315(e), which only applies after a final written decision and is limited to grounds that were raised or reasonably could have been raised.

The practical impact creates an all-or-nothing decision at the IPR filing stage. Companies facing patent assertion would forfeit all anticipation and obviousness defenses in district court – even those not included in their petition – if they file an IPR petition and it is instituted. This dramatically raises the stakes for IPR filings and may discourage challenges to questionable patents.

Absolute Bar Following Prior Challenges

Perhaps the most significant change involves proposed § 42.108(e), which would prohibit IPR institution against claims that have survived any prior §§ 102/103 validity challenge in district court, the International Trade Commission (搜索)搜索该词条 (ITC), or previous USPTO (搜索)搜索该词条 proceedings. Unlike the current discretionary framework under 35 U.S.C. § 325(d), this creates a mandatory bar with no exceptions for new prior art or arguments.

This "first mover" problem particularly benefits non-practicing entities (NPEs) who can strategically select weak first defendants. If you are the second or subsequent defendant sued on a patent, you may have no IPR option if an earlier defendant mounted any validity challenge – even if that challenge was poorly executed, settled early, or based on inferior prior art.

Parallel Proceedings Prohibition

The proposed amendments would categorically bar IPR institution when a district court trial or ITC determination "will more likely than not" occur before the PTAB's deadline for a final written decision. This replaces the current discretionary Fintiv analysis with a bright-line rule.

Patent owner plaintiffs can effectively block IPR access by filing in rocket dockets like the Western District of Texas (搜索)搜索该词条, where trials routinely occur within 18 months. Even if circumstances change – such as trial delays or potential stays – the initial "more likely than not" determination would be binding.

Limited Extraordinary Circumstances Exception

The proposed amendments permit subsequent IPR challenges only under "extraordinary circumstances," which are significantly narrowed to situations such as prior bad faith conduct or intervening changes in the law. Discovery of new prior art, inadequate prior representation, or clear errors in earlier proceedings would not qualify. Frivolous or abusive petitions would be subject to sanctions and attorneys' fees.

The exception is so narrow as to be virtually meaningless for most patent defendants. Even breakthrough prior art discovered after an initial challenge would not justify a second IPR attempt against the patent.

Industry-Specific Implications

Pharmaceutical and Biotechnology Sector

The proposed amendments particularly benefit branded pharmaceutical companies by making it harder for generic manufacturers to challenge patents through IPR. Subsequent generic filers may be bound by inadequate challenges from first filers, potentially extending market exclusivity.

Technology and Software Companies

Technology companies facing assertions from NPEs will be most negatively impacted. NPEs can leverage the rules to protect weak patents by ensuring initial challenges come from resource-constrained defendants, then asserting those "validated" patents against major industry players.

Manufacturing and Consumer Products

Companies in competitive industries where cross-assertions are common must carefully consider whether IPR remains viable given the mandatory stipulation requirements. District court litigation may become the only option for comprehensive validity challenges.

Strategic Response Requirements

Companies that may face patent assertions should immediately assess any pending patent disputes to determine whether IPR petitions should be filed before the new rules may take effect. Immediate coordination with co-defendants is essential, as the first filer may determine everyone's fate under the proposed framework.

The USPTO (搜索)搜索该词条 frames these changes as promoting efficiency and quiet title, citing "broad discretion" conferred by Congress in determining when to institute review. The proposed rule changes lodge criticisms of the current post grant review system, alleging a weakening of patent rights and related economic harm resulting from abuses of the current system.

However, the practical effect would likely be to shield questionable patents from review while dramatically increasing litigation costs for innovative companies. The rules represent the most significant restriction on IPR accessibility since the America Invents Act created the procedure in 2012, essentially creating a "one and done" system for validity challenges.